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Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder, is caused by mutations in the dystrophin (DMD) gene. Exon skipping is a therapeutic approach that uses antisense oligonucleotides (AOs) to modulate splicing and restore the reading frame, leading to truncated yet functional protein expression. In 2016, the FDA conditionally approved the first phosphorodiamidate morpholino oligomer (morpholino)-based AO drug, eteplirsen, developed for DMD exon 51 skipping. Eteplirsen remains controversial with insufficient evidence of its therapeutic effect in patients. We recently developed an in silico tool to design antisense morpholino sequences for exon skipping. Here, we designed morpholino AOs targeting DMD exon 51 using the in silico tool and quantitatively evaluated the effects in immortalized DMD muscle cells in vitro. To our surprise, most of the newly designed morpholinos induced exon 51 skipping more efficiently compared to the eteplirsen sequence. The efficacy of exon 51 skipping and rescue of dystrophin protein expression were increased by more than 10-fold compared to the eteplirsen sequence. Significant in vivo efficacy of the most effective morpholino, determined in vitro, was confirmed in mice carrying the human DMD gene. These findings underscore the importance of AO sequence optimization for exon skipping.
Introduction 
Duchenne muscular dystrophy (DMD) is one of the most prevalent lethal genetic disorders in boys worldwide, with an incidence of approx. 1 in 3,600 – 9,337 live male births  ADDIN EN.CITE 1. DMD is caused by the absence of dystrophin protein due to mutations in the dystrophin (DMD) gene 2. Currently one of the most promising therapeutic avenues is exon skipping using antisense oligonucleotides (AOs) 3. Exon skipping can restore the reading frame by removing the mutant exon and/or its flanking exon(s) from the DMD pre-mRNA  ADDIN EN.CITE 4-13, enabling the production of truncated but partly-functional dystrophin protein as seen in the milder counterpart disorder, Becker muscular dystrophy (BMD)  ADDIN EN.CITE 14-16. A majority of DMD patients harbour deletion mutations and 20% of these are amenable to exon 51 skipping  ADDIN EN.CITE 17. 
In September 2016, the US Food and Drug Administration (FDA) approved the first DMD antisense drug, eteplirsen (Exondys 51), which was developed to exclude exon 51 from mutant DMD 18. Eteplirsen is an AO modified with a phosphorodiamidate morpholino oligomer (morpholino or PMO), an antisense chemistry that has been well-established in terms of its safety and effectiveness  ADDIN EN.CITE 19,20. The FDA’s approval of eteplirsen remains controversial as their decision was made with very weak evidence supporting the effectiveness of the drug, both in terms of both restoring dystrophin protein to therapeutically beneficial levels, and improving clinical outcomes  ADDIN EN.CITE 21-27. The FDA has previously rejected another drug candidate for DMD exon 51 skipping: the 2’-O-methyl-phosphorothioate-based AO, drisapersen, as no significant improvements in muscle function and its toxicity were demonstrated  ADDIN EN.CITE 28. Exon skipping therapy currently faces a major challenge in that its observed efficacy in patients has been very low despite the fact that significant therapeutic effects have been demonstrated in many animal studies..
It is obvious that exon skipping efficiency is largely dependent on the AO target sequence: however, there has been little debate on the notion that the sequences targeted by eteplirsen and drisapersen might not be the optimal choices for exon skipping therapy 29. Several groups have undertaken large-scale AO screening efforts to determine effective AO sequences both computationally and empirically. However, the exon skipping effectiveness of designed AOs has not been evaluated both quantitatively and statistically  ADDIN EN.CITE 4,7,10,13,30. Although restoring dystrophin protein expression is necessary to improve dystrophic muscle function, the ability of AOs to rescue dystrophin protein expression has not been reported in previous AO screening studies. It is remarkable that the AO sequences of eteplirsen and drisapersen were determined within this context  ADDIN EN.CITE 7. Thus, there remains the possibility that the effectiveness of exon 51 skipping therapy could be improved by selecting more optimal AO sequences. This also further underlines the need for rigorous AO screening using a more reliable and direct biological measure – such as rescued dystrophin protein in DMD – for validating an AO to be tested in a clinical trial. 




In silico screening of AOs for exon 51 skipping.
We designed total 413 AOs: 204 and 209 AOs with 30-mer and 25-mer lengths, respectively, which cover all possible target sites in DMD exon 51. Our exon skipping efficiency algorithm 31 predicted that the highest efficiency for exon 51 skipping was 80.5% for 30-mer AOs, and 41.2% for 25-mer AOs in the initial 5’ site of exon 51 (Supplemental Table S1). In silico screening indicated a very low exon skipping efficiency for the 30-base region targeted by eteplirsen (23.7%), which was ranked 92nd  in all 413 AO candidates tested. The same calculation could not be done for 20-mer drisapersen as our predictive model was based on 25- and 30-mer-long sequences; in any case, the drisapersen target site is completely encompassed by that of the 30-mer eteplirsen. 
Characterization of immortalized clonal healthy and DMD skeletal muscle cell lines
Significant issues in preclinical testing with primary DMD muscle cells include low purity of muscle cells and insufficient amounts of mutant dystrophin mRNA, which present problems when trying to test AO efficacy. To overcome these hurdles, we generated immortalized clonal skeletal muscle cells from 3 healthy subjects and 2 DMD patients with exon 52 (ex52) and ex48-50 deletion (del.) mutations (IDs KM571 and 6594, respectively) 32. All immortalized skeletal muscle cell lines tested expressed easily-detectable dystrophin mRNA from day 3 after induction of differentiation (Supplemental Figure S1A). To avoid overestimation of dystrophin protein levels induced by AOs in DMD cells, we selected a cell line (ID 8220) with the highest level of dystrophin protein among three immortalized healthy skeletal muscle cell lines as determined by Western blotting to serve as a positive control (Supplemental Figure S1B and C). Dystrophin protein expression in the 8220 cell line was also confirmed by immunocytochemistry (Supplemental Figure S1D). 
In vitro screening of exon 51 skipping AOs
Based on the in silico screening results, we selected eight 30-mer AOs spaced at least 4 bases apart from each other for in vitro screening (Table 1). In the present study, all tested AOs, including eteplirsen and drisapersen sequences, were synthesized using the morpholino chemistry that has been demonstrated to be well-tolerated in patients enrolled in clinical trials 20. Here, we termed morpholinos having the same sequences as eteplirsen and drisapersen (produced by Gene Tools) as “analog eteplirsen” and “analog drisapersen”. In RT-PCR, 5 of our morpholino AOs (Ac0, Ac5, Ac26, Ac30 and Ac48) at 10 μM showed significantly higher skipping efficiency compared to analog eteplirsen and drisapersen in immortalized DMD skeletal muscle cells harboring ex52 del. (Figure 1A). Of the tested AOs, Ac0 in particular had the highest skipping efficiency, reaching up to 72%, which was 4 and 25 times more efficient than analogs of eteplirsen and drisapersen, respectively. In Western blotting, Ac0 also induced the highest levels of dystrophin protein, reaching up to 16% of levels in the healthy control cell line, followed by Ac48 at 13% (Figure 1B).
Time-course analysis with Ac0, Ac48, and analog AOs of eteplirsen and drisapersen
The persistent effects of Ac0, Ac48, and analogs of eteplirsen and drisapersen at 5 μM were examined in ex52 del. KM571 cells. The superiority of Ac0 to Ac48, with respect to exon skipping efficiency and dystrophin protein rescue, was observed at days 2 and 11 post-transfection compared to analog AOs of eteplirsen and drisapersen (Figure 2).
Dose-dependent effects of Ac0, Ac48, and analog eteplirsen and drisapersen
RT-PCR showed that Ac0 at the highest concentration of 10 μM induced up to 74% and 64% exon 51 skipping in DMD KM571 (ex52 del.) and 6594 cells (ex48-50 del.), respectively, which were significantly higher than Ac48, analogs of eteplirsen and drisapersen (Figure 3). At the lowest concentration (1 μM), Ac0 showed 12 and 10 times higher exon skipping efficiency compared to analog eteplirsen in KM571 and 6594 cells, respectively. Interestingly, 1 μM Ac0 induced higher levels of exon 51 skipping than 10 μM analog eteplirsen (24% efficiency vs 15% in KM571 and 24% efficiency vs 21% in 6594, respectively). Quantitative Western blotting revealed that 10 μM Ac0 rescued dystrophin protein expression in DMD cell lines up to 21% of healthy cell line levels (Figure 3A and B). At 1 μM, the relative ratio of Ac0 to analog eteplirsen represented 7.1 and 3.3 times higher efficiency in producing dystrophin proteins in KM571 and 6594 cell lines, respectively. Ac0 at 1 μM enabled the production of rescued dystrophin protein at higher or comparable levels than analog eteplirsen at 10 μM (10% vs 6% in KM571 and 11% vs 10% in 6594, respectively), confirming that Ac0 is more than 10-fold effective at producing dystrophin protein compared to analog eteplirsen concentration-wise. Analog drisapersen did not work effectively for both exon skipping and dystrophin production in the DMD muscle cell lines. The exon skipping response to Ac0 and Ac 48 occurred in a dose-dependent manner that was greater than analog eteplirsen, and analog drisapersen (Figure 3C). The dose-responsiveness of Ac0 with respect to dystrophin protein production was also higher than the analog ones in both DMD cell lines.  
Immunocytochemical assessment of dystrophin protein rescue 
Immunocytochemistry revealed that Ac0 and Ac48 at 10 μM yielded more dystrophin-positive myotubes and displayed stronger signal intensity in DMD skeletal muscle cell lines harboring ex52 and ex48-50 del. mutations compared to analog eteplirsen (Figure 4).
Length optimization of Ac0 morpholino
In silico and in vitro screening revealed that the initial 5’ region of exon 51 is an important region for influencing exon 51 skipping. To optimize the sequence length of Ac0 targeting this region, we compared the skipping efficiencies of Ac0 morpholinos of different lengths (25- to 30-mer), in which nucleotides at the 5’ site were systematically removed (Table 1). In vitro testing in immortalized DMD muscle cells treated with 1 μM of these AOs showed that 25 – 30-mer Ac0 morpholinos produced efficient exon skipping (> 20%), an effect that was not observed with Ac48, analog eteplirsen, and analog drisapersen at the same dose. The statistically significant effectiveness of 30-mer Ac0 was confirmed at 1 and 3 μM doses compared to the shorter Ac0 morpholinos in both cell lines.
Effect of Ac0, Ac48, and analog eteplirsen and drisapersen on primary DMD patient-derived skeletal muscle cells
We also tested the AOs in primary DMD skeletal muscle cells with exons 45-50 (ID 4546) or exons 49-50 del. mutations (ID 4555) to validate if the superior efficacy of 30-mer Ac0 is consistent for other muscle cell types and deletion mutation patterns. RT-PCR showed that Ac0 achieved significantly higher exon skipping efficiency in both primary DMD muscle cells compared to Ac48, analog eteplirsen, or analog drisapersen (Figure 6A to D): up to 5 and 7 times higher efficiency were observed compared to analog eteplirsen and drisapersen, respectively. A significant efficiency of Ac0-mediated exon 51 skipping was also confirmed in primary healthy skeletal muscle cells (Figure 6E and F). Interestingly, with increasing exon 51 skipping efficiency, spontaneous exon 52 skipping, which does not disrupt the reading frame, was observed in primary healthy and DMD muscle cells, and an immortalized DMD muscle cell line with ex48-50 del. (6594) (Supplemental Figure S3).
Efficacy of murine Ac0, Ac48, eteplirsen and drisapersen in mdx52 mice
To test the suitability of an in vivo animal model as an alternative tool to screen AO drug candidates for patients, we performed intramuscular injections of mouse versions of human Ac0, Ac48, eteplirsen and drisapersen sequences into the tibialis anterior (TA) muscles of Dmd exon 52-deleted mdx52 mice (Supplemental Figure S4A). Unlike the results of the in vitro screening in human cell models, no significant differences in exon 51 skipping efficiency or dystrophin protein rescue were observed between mouse versions of Ac0, Ac48 and eteplirsen (Supplemental Figure S4B and C). In immunohistochemistry, all mouse analog AOs showed extensive expression of dystrophin-positive myofibers, with the signal intensity consistently increasing with administrated dose (5 and 20 μg) (Supplemental Figure S4D). These results indicate that effective regions for exon skipping in the human DMD gene are different from those in animals.
In vivo efficacy of Ac0 morpholino and analog eteplirsen in hDMD/Dmd-null mice
A major hurdle in the development of exon skipping therapy is that human-specific AOs cannot always be tested in an appropriate animal model. This limits the evaluation of in vivo effects of AOs designed for patients. Here, we developed a new mouse model that has the human DMD gene but lacks the mouse Dmd gene to test the in vivo efficacy of human AOs. Ac0 or analog eteplirsen was injected into TA muscles of these mice, and the effectiveness of in vivo exon 51 skipping was analyzed 2 weeks after the injection. The result showed significantly grater exon skipping efficiency in mice treated with Ac0 compared to analog eteplirsen (Figure 7). 
Discussion
Currently, a major challenge for antisense-mediated exon skipping in DMD is that there has been little demonstrated therapeutic efficacy of exon 51 skipping with drisapersen or eteplirsen  ADDIN EN.CITE 18,28. While drisapersen was rejected, the FDA approved eteplirsen. However, at the same time the FDA review team also stated that functional improvement with the drug was not proven 18. Controversy over the approval process was centred on whether the amount of dystrophin protein produced by the drug is sufficient to be reasonably likely to translate to a clinical benefit. The rescued dystrophin levels induced by eteplirsen were reported to be in the range of up to 0.28% of healthy muscle as detected by Western blotting, which is far less than the 10% of therapeutically beneficial levels estimated from BMD patients and preclinical trials. A lesson learned from the clinical trials is that greater dystrophin protein rescue is needed for patients to gain significant clinical benefits. These cases compel us to return to a basic concept of exon skipping: that the target sequence of a given AO primarily determines the therapeutic effect of the strategy. 
Here, through evaluation of AOs designed using computational and experimental approaches, we revealed that the efficacy of exon 51 skipping largely depends on the given AO sequences and/or its target positions within the DMD gene. We have previously developed machine-learning algorithms to predict the exon skipping efficiency of designed AOs 31. While, in theory, the number of AOs for a target exon reaches hundreds of candidates, in practice, all of them will not be empirically tested. Although the evaluation of AO sequences and/or the nature of a target exon is the first screening step for identifying an AO for clinical use, no quantitative method to predict exon skipping efficacy has been available to give a robust rationale for AO sequences to take in vitro screening. Because of this, many effective AO sequences may have been overlooked in previous screening efforts. Our AO predictive software tool quantitatively predicted that the initial 5’ site of exon 51 was a potentially important region for inducing exon 51 skipping, whereas the internal region targeted by eteplirsen or drisapersen was predicted to have lower efficiency. Through in silico screening, 91 of 413 AOs, which encompass the entire exon 51 with 30- or 25-mer in length, were revealed to be potentially more effective at exon 51 skipping than the 30-mer eteplirsen sequence. In contrast, the second best AO sequence (Ac48), as determined by in vitro screening, was computationally predicted to have a lower exon skipping efficiency than the eteplirsen sequence. As such, while the present prediction software cannot completely substitute for in vitro screening, the use of a precise computational assessment as the first screening step remains useful, as it can greatly help prevent the oversight of potentially effective AO sequences. The accuracy of in silico AO prediction could still be further improved by integrating additional factors influencing exon skipping into the algorithm, such as chemical properties of AOs (e.g. cell membrane permeability and turnover in target cells) and pre-mRNA conformational landscapes/accessibility of designed AOs to target RNA sites altered by DMD mutations.
It is clear that the efficacy of exon skipping as a therapy for DMD correlates with the expression levels of rescued dystrophin protein, a key determinant of whether or not muscle function will be improved by treatment. This highlights the need for a way to assess the ability of AOs to restore dystrophin protein production in vitro. As the effectiveness of human-specific AOs cannot always be examined in humanized animal models harboring applicable DMD mutations, in vitro screening using DMD patient-derived muscle cells is of great importance, representing a final stage at present for assessing the ability of AOs to produce dystrophin protein from DMD mutant variants. Primary DMD muscle cells are the most widely used cell type in AO screening efforts, but they do not always express sufficient levels of mutant DMD mRNA for properly examining exon skipping efficiency. This has been evidenced by the fact that in previous screening methods, exon skipping efficiency has been assessed with extra PCR cycles, using a nested PCR approach that likely overestimates levels of skipped transcripts  ADDIN EN.CITE 4-11,13. Accordingly, quantitative screening of exon 51 skipping AOs based on their ability to rescue dystrophin protein has never been reported in primary DMD cells  ADDIN EN.CITE 4,7,10,13,30 In this study, we demonstrated the feasibility of AO screening via quantification of dystrophin protein induced by exon 51 skipping using immortalized DMD patient cell lines. Through a combination of in silico and in vitro screening, morpholino-based AOs showed significantly greater effectiveness at facilitating exon 51 skipping and rescuing dystrophin protein expression than sequences of eteplirsen and drisapersen. The most effective AO, Ac0 displayed 10-fold greater exon skipping efficacy compared to analog eteplirsen and drisapersen. This indicates that in vitro screening with an appropriate DMD cell model (such as immortalized DMD cells) expressing sufficient DMD mRNA for the evaluation of exon skipping effect can help reveal the therapeutic potential of designed AOs for progression into clinical trials. 
We previously described that the accessibility of an AO to a target site could be a factor influencing exon skipping efficiency because of altered RNA conformation due to a mutation 31. Throughout the in vitro tests using immortalized or primary DMD muscle cells, the statistically significant effectiveness of Ac0 morpholino was consistently observed in 4 mutation patterns that have also been tested in eteplirsen or drisapersen clinical trials  ADDIN EN.CITE 28,37. However, the assessment of therapeutic outcomes from exon 51 skipping needs to be carefully considered due to differences in the functionality and stability of truncated proteins, arising from structural differences owing to variously-skipped exons, as observed in BMD phenotypes with different in-frame mutations  ADDIN EN.CITE 38,39.
As revealed in the present study using mdx52 mice, effective AO sequences and/or target positions to skip a certain exon are different between species, which had not previously been demonstrated. An hDMD mouse model with the normal human DMD gene may be a solution for assessing in vivo efficacy of human-specific AOs. As hDMD mice retain the normal mouse Dmd gene, which could interrupt the precise evaluation of efficacy with a human AO, the hDMD/Dmd-null mouse, as developed here, could be a more appropriate model. Using this model, we confirmed the significantly greater in vivo exon 51 skipping efficiency of Ac0 than analog eteplirsen. As the hDMD/Dmd-null mouse model is not a disease model, our ability to produce DMD mutations of interest in this model could make feasible the assessment of dystrophin protein rescue by human-specific AOs. Together with the development of such humanized animals, access to a precise in silico screening system and a variety of immortalized DMD muscle cell lines with different mutations will enhance our capacity to find AO drug candidates targeting other DMD exons.
Although eteplirsen might have some potential for treating DMD, the drug will retail for over 300,000 US dollars/patient/year 24, an impassable hurdle for many patients who lack the resources to cover such an expense. Further clinical utility of the drug would be revealed by May 2021 with the FDA-requested clinical trial 18. The European Medicines Agency (EMA) has also validated a Marketing Authorization Application for conditional approval of eteplirsen (PIP number: EMEA-001722-PIP01-14-M01). Whatever the results, one thing for certain is that patients and their families definitely need and deserve an effective therapy that is commensurate with its cost. Hence, we need to pursue developing better antisense drugs from which patients can be assured of receiving therapeutic benefits.
In conclusion, the present study demonstrates that the development of more effective antisense morpholino drugs for exon 51 skipping is feasible, further supporting the feasibility of dystrophin protein rescue via exon skipping in DMD patients. Our study validated that a key component of success in exon skipping therapy is selecting the right AO sequence. We also described a model of a systematic AO screening using the quantification of both potential exon skipping efficiency and rescued dystrophin protein levels for the selection of an optimal AO sequence to be tested in a clinical trial. Using this screening method we identified an AO sequence, Ac0, that was significantly more effective at rescuing dystrophin protein expression when compared with clinically-investigated AO sequences. Finally, we note that the screening process of an AO drug candidate needs to be more recognized by regulators, patients, advocates, and scientists so that their decision and expectation regarding the candidate drug can be made in the same direction. 
Materials and methods
Design and in silico screening of AOs. 413 30-mer and 25-mer AOs targeting exon 51 were designed and analyzed using the AO predictive algorithm we recently developed (Supplemental Table 1) 31. Based on predicted exon skipping efficiencies, 8 AOs spaced at least 4 bases apart were selected for in vitro screening (Table 1). Target sequence specificities of selected AOs, eteplirsen, and drisapersen were analyzed using The University of California, Santa Cruz Genome Browser (http://genome.ucsc.edu/index.html (​http:​/​​/​genome.ucsc.edu​/​index.html​)), confirming that the AO sequences theoretically do not bind any non-target RNA sequences with 100% identity. 
Antisense morpholinos. All antisense sequences, including analog AOs of eteplirsen and drisapersen, were synthesized with the morpholino chemistry by Gene Tools.
Cells. Immortalized human skeletal muscle cells derived from three healthy subjects (IDs 8220, CHQ, and KM155) and two DMD patients harboring deletion mutations of exon 52 (ID KM571) and exons 48-50 (ID 6594) in the DMD gene, respectively, were generated by transduction with human telomerase-expressing and cyclin-dependent kinase 4-expressing vectors in the Institute of Myology human cell immortalization platform, as previously described 32. The three immortalized healthy muscle cell lines were characterized and the clonal line 8220, which showed the highest dystrophin expression was selected as a positive control to prevent overestimation of rescued dystrophin expression in immortalized DMD cells. Primary skeletal muscle cells derived from DMD patients with deletion mutations of ex45-50 (ID 4546) and ex49-50 (ID 4555) and a healthy subject were prepared by the BioBank of Skeletal Muscle, Nerve Tissue, DNA and cell lines.
AO transfection. To mimic as closely as possible the in vivo effects of AO-mediated exon skipping therapy, mature, differentiated myotubes expressing sufficient levels of DMD mRNA were used for in vitro screening. Cells were cultured in proliferation conditions with growth medium (GM): DMEM/F12 with skeletal muscle supplement mix (Promocell), 20% fetal bovine serum, and antibiotics (50 units penicillin and 50 μg/ml streptomycin). Immortalized and primary DMD skeletal muscle cells were seeded at 1.7 x 104/cm2 and 2.2 x 104/cm2, respectively, in collagen type I-coated 12 or 24-well culture plates. Two days after seeding, at approximately 80-90% confluence, GM was replaced with differentiation medium (DM): DMEM/F12 with 2% horse serum, 1x ITS solution (Sigma), and antibiotics. After three days in DM, cells were transfected with AO at 1, 3 or 10 μM containing 6 μM of Endo-porter transfection reagent (concentrated AOs at 1 mM were incubated at 65ºC for 10 min just before diluting with DM). Two days following AO transfection, AO-containing DM was replaced with regular DM. Cells were harvested at day 2, 5, or 11 after AO transfection (day 5, 8 or 14 following differentiation). A schematic of the culture plan is shown in Supplemental Figure 2. 
Mice. Animal studies were approved by the Animal Care and Use Committee at the University of Alberta, Children's National Medical Center, and National Center of Neurology and Psychiatry (NCNP). Male and female Dmd exon 52-deficient mdx52  ADDIN EN.CITE 33 and wild-type mice (Jackson laboratory) with a C57BL/6J background were prepared at age 4-8 weeks. Dmd mutation in affected mice was confirmed by genotyping with PCR. A transgenic mouse model harboring the human DMD gene and lacking the mouse Dmd gene (hDMD/Dmd-null mouse) was generated by cross-breeding male hDMD mice (Jackson laboratory) with female Dmd-null mice  ADDIN EN.CITE 34. 
Intramuscular injection. Mouse version morpholinos of Ac0, Ac48, eteplirsen or drisapersen at 5 or 20 μg in 40 μL saline were intramuscularly injected into tibialis anterior (TA) muscle under inhalation anesthesia with isoflurane as previously described (Supplemental Figure S3A)  ADDIN EN.CITE 35. Fifty-μg of Ac0 morpholino and analog eteplirsen in 30 μL saline was injected into TA muscles of hDMD/Dmd-null mice. All muscle samples were harvested 2 weeks after intramuscular injection.
Exon skipping analysis by RT-PCR. Total RNA was extracted with Trizol (Invitrogen) as previously described  ADDIN EN.CITE 31,35. RT-PCR to detect dystrophin mRNA was performed with the SuperScript III One-Step RT-PCR System (Invitrogen) and 0.2 μM of forward and reverse primers (Supplemental Table 2) for 200 ng and 320 ng of total RNA in immortalized and primary skeletal muscle cells, respectively. Primers were designed using Primer3Plus software and their specificity was confirmed in healthy human skeletal muscle cells (line 8220). The RT-PCR conditions were as follows: 50 °C for 5 minutes; 94 °C for 2 minutes; 35 cycles at 94 °C for 15 seconds, 60 °C for 30 seconds, and 68 °C for 35 seconds; and 68 °C for 5 minutes. PCR products were separated on a 1.5% agarose gel and visualized by SYBR Safe DNA Gel Stain (Invitrogen). Using ImageJ software (NIH) or the MCE-202 MultiNA system (Shimadzu), the efficiency of exon 51 skipping was calculated using the following formula: exon 51-skipped transcript intensity / (native + intermediate + exon 51-skipped transcript intensities) × 100 (%). Unknown top bands above the native band were excluded from quantification of skipping efficiency. The sequences of the PCR products were confirmed with Big Dye Terminator v3.1 (Applied Biosystems). GAPDH or 18S ribosomal RNA was used as an internal control.
Western blotting. Cells were harvested with RIPA buffer (Thermo Scientific) containing cOmplete, Mini, EDTA-free protease inhibitor cocktail (Roche), and then homogenized by passing through a 21-gauge needle 10 times. The supernatants as loading samples were prepared by centrifugation at 14,000 g for 15 min at 4ºC. Protein from muscle tissues were prepared as previously described  ADDIN EN.CITE 35. Protein concentrations were adjusted using the Bradford assay with supernatants diluted 100 times with water. Proteins in a sample buffer containing 10% SDS, 70 mM Tris-HCl, pH 6.8, 5 mM EDTA, 20% glycerol, 0.004% bromophenol blue and 5% 2-mercaptoethanol were heated at 70ºC for 10 min. Twelve-μg and thirty-μg from cells and tissues, respectively, were separated on a NuPAGE Novex 3–8% Tris-Acetate Midi Gel (Invitrogen) by sodium dodecyl sulfate–polyacrylamide gel electrophoresis at 150 V for 75 minutes. Separated proteins in the gel were transferred onto an Immobilon PVDF membrane (Millipore) by semidry blotting at 20 V of constant voltage for 70 minutes with a discontinuous buffer system. The membrane was blocked with 2% enhanced chemiluminescence (ECL) blocking reagent (GE Healthcare) in phosphate-buffered saline containing 0.05% Tween 20 (PBST) overnight at 4°C. Blots were incubated with a rabbit polyclonal antibody against dystrophin C-terminal (1:2500, ab15278, Abcam) in the blocking solution or DYS1 antibody against dystrophin rod domain (1:400, Novocastra) for 1 hour at room temperature. The primary antibody was reacted with HRP-conjugated anti-rabbit or mouse IgG H+L antibody (1:10,000). Signals were detected with the ECL select detection reagent (GE Healthcare). Expression levels of dystrophin protein induced by AOs were quantified using calibration curves from dystrophin protein of healthy 8220 skeletal muscle cells diluted with protein from non-treated DMD cells, or wild-type mouse using ImageJ (NIH). Alpha-tubulin was detected on the same membrane as a loading control. Myosin heavy chain (MyHC) on post-transferred gels was stained with Coomassie Brilliant Blue as a loading control/differentiation marker.     
Immunocytochemistry. Cells were fixed with 4% paraformaldehyde for 5 min at room temperature. After washing with PBS containing 0.01% Triton X-100, cells were blocked with 10% goat serum in PBS with 0.05% Triton X-100 for 20 min and then incubated with anti-dystrophin C-terminal (ab15278) or rod-domain (DYS1) antibody at 1:50 dilution in blocking solution overnight at 4ºC. Dystrophin signals were detected with Alexa 488- or 594-conjugated secondary antibody (1:500). Desmin (1:80, Abcam) and MyHC-fast type (1:30, Novocastra) were detected to confirm myogenic differentiation of cells. Cells were stored in SlowFade Gold Antifade Mountant with DAPI (Invitrogen) at 4ºC until analyzed. 
Immunohistochemistry. Dystrophin-positive muscle fibers on cryosections from TA muscles of non-treated and treated mdx52 mice were detected with the ab15278 antibody as previously described 36. Signal intensity of dystrophin in the treated mice was compared with that in wild-type using neutral density filters (Eclipse TE 2000-U, Nikon).
Statistical analysis. For determining the significance of efficiencies in exon skipping and dystrophin protein rescue, data sets were prepared from at least three independent experiments in immortalized cells, triplicate wells in primary cells, and 3 – 7 mice. The statistical analysis between AO-treated groups was performed by one-way ANOVA followed by a post hoc Tukey–Kramer multiple comparison test. Simple linear regression analysis was performed for dose-responsiveness to AOs. Statistical significance was set at p<0.05 for all analyses.
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Figure 1. In vitro screening of designed antisense oligonucleotides (AOs) and analog AOs of eteplirsen (aEte) and drisapersen (aDri) at 10 μM, in immortalized clonal exon 52-deleted DMD skeletal muscle cells (KM571). Differentiated myotubes were harvested at day 5 following transfection. (A) Efficiency of exon 51 skipping as measured by one-step RT-PCR. Representative images are shown. M, 100 bp marker; blank, no RNA template. (B) Efficiency in inducing truncated dystrophin protein as measured by quantitative Western blotting with the anti-dystrophin C-terminal antibody. Rescued dystrophin protein levels are calculated using calibration curves with healthy 8220 cells. Data represent mean ± SD from 3-4 independent experiments. ** p<0.01 vs aEte, † p<0.05 and †† p<0.01 vs aDri, §§ p < 0.01 vs all of AOs in (A) and vs Ac0 in (B).

Figure 2. Time-course analysis of dystrophin exon 51 skipping and protein in an exon 52-deleted DMD-KM571 cell line transfected with Ac0, Ac48, and analog AOs of eteplirsen and drisapersen at 5 μM. Samples were collected at days 2 and 11 post-transfection. (A) RT-PCR analysis of exon 51 skipping. M, 100 bp marker; R, replicate number; blank, no RNA templates. (B) Quantification of induced dystrophin protein by Western blotting with the anti-dystrophin C-terminal antibody. Representative replicates from 3 independent experiments are shown.

Figure 3. Dose-dependent analysis of Ac0, Ac48, and analogs of eteplirsen and drisapersen in DMD exon 52 del. (A) and exons 48-50 del. muscle cells (B) as measured by one-step RT-PCR and quantitative Western blotting. Both cell lines were transfected with AOs at 1, 3, and 10 μM and harvested at day 5 post-transfection. Data represent mean ± SD from 3-7 independent experiments in the KM571 cell line and from 3-4 independent experiments in the 6594 cell line. * p<0.05, ** p<0.01 vs aEte; † p<0.05 and †† p<0.01 vs aDri; § p<0.05, §§ p<0.01 vs Ac48 in the same concentration, NS, no significance vs Ac0 at the next dose; ns, no significance vs Ac0 at 10 μM. (C) Dose-responsiveness to the AOs analyzed by regression model. Statistical validity of regression equations in skipping and producing dystrophin protein was p<0.008 and p<0.014, respectively. Plots indicate values of exon skipping or dystrophin protein levels predicted in the regression analysis. The regression slope and 95% confidence interval (CI) are shown in individual AOs.

Figure 4. Immunocytochemistry in immortalized DMD patient-derived skeletal muscle cells with exon 52 (ID KM571) and exons 48-50 deletion mutations (ID 6594). Cells at day 5 post-transfection with Ac0, Ac48, and analog eteplirsen (aEte) were stained with anti-dystrophin C-terminal antibody. Red signals indicate dystrophin-positive myotubes. Blue signals indicate nuclei counter-stained with DAPI. * indicates representative false-positive myotubes due to their contraction or detachment from the culture plate. Representative images are shown from 3 independent experiments. Scale bar: 100 μm.

Figure 5.  Length optimization of Ac0 morpholino. Immortalized DMD muscle cells were transfected with Ac0 morpholinos composed of 25-, 26-, 27-, 28-, 29-, and 30-mer. A representative image and quantification of exon 51 skipping induced by Ac0 morpholinos at 1 μM (A and B) and 3 μM (C and D) in DMD muscle cells with exon 52 deletion (KM571) are shown as represented by RT-PCR. (E – H) indicate the results in immortalized DMD cells with exons 48-50 deletion. The data are shown from 3 independent experiments.

Figure 6. Exon 51 skipping efficiency induced by Ac0, Ac48, analog AOs of eteplirsen (aEte) and drisapersen (aDri) in primary DMD and healthy skeletal muscle cells. Differentiated myotubes were transfected with Ac0, Ac48, and analog eteplirsen and drisapersen at 10 μM, and then harvested 3 days later. Exon 51 skipping efficiency as represented by one-step RT-PCR was shown in primary DMD cells with the deletion mutation of exons 45-50 (ID 4546) (A and B) or exons 49-50 (ID 4555) (C and D), and primary healthy muscle cells (E and F). Data represent mean ± SD from at least triplicate wells in each condition. M, 100 bp marker. ** p<0.01 vs aEte, † p<0.05 and †† p<0.01 vs aDri, §§<0.01 vs Ac48.

Figure 7. In vivo efficacy of 30-mer Ac0 antisense morpholino in the hDMD/Dmd-null mouse model. Exon skipping efficacy was analyzed by RT-PCR with tibialis anterior muscles 2 weeks after the intramuscular injection of Ac0 morpholino or analog eteplirsen (50 μg in 30 μL saline). (A) Densitometry analysis of exon 51 skipping as represented by a microchip based capillary electrophoresis system. (B) Averaged percentage of exon 51 skipping efficiency (mean ±SE). N = 7 in each group. M, marker; NT, non-treated muscle, UM, upper marker dye; LM, lower marker dye.
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Legends of supplementary information 
Figure S1. Expression analyses of dystrophin in immortalized clonal healthy and DMD skeletal muscles cells. (A) Time-course analysis by one-step RT-PCR to confirm dystrophin mRNA expression in immortalized healthy (Cell IDs 8220, CHQ and KM155) and DMD skeletal muscles cells with deletion mutations of exon 52 (ID KM571) and exons 48-50 (ID 6594). Target regions of dystrophin mRNA in healthy and DMD cells were amplified with 26 and 35 cycles, respectively, in the RT-PCR condition described in the materials and methods. M, 100 bp marker. (B) Western blotting to select a positive control immortalized healthy skeletal muscle cell line. Protein samples (1.2 μg) from the cells at day 8 post-differentiation were loaded. Dystrophin was detected by ab15277 antibody against the dystrophin C-terminal. MyHC on a post-transferred gel was stained with Coomassie Brilliant Blue. (C) Time-course analysis of dystrophin protein amount in 8220 by Western blotting with DYS1 antibody. Protein samples (5 μg) of the cells at day 0, 3, 6, 9 and 12 post-differentiation were loaded. (D) Immunocytochemistry with anti-dystrophin (DYS1 or ab15277) antibody to examine localization of dystrophin (red) on the sarcolemma in healthy 8220 myotubes. Images are representative with DYS1 antibody. Anti-desmin (green) and myosin heavy chain (MyHC) fast-twitch (red) antibodies were used to confirm myogenic lineage of the cells. DAPI (blue) was used for counter-staining of nuclei. Scale bar, 200 μm.

Figure S2. Schematic of transfection of DMD skeletal muscle cells with antisense oligonucleotides (AOs). GM, growth media; DM, differentiation media. A red arrow with dots indicates a day for collecting transfected primary DMD muscle cells.
	
Figure S3. Spontaneous exon 52 skipping along with AO-mediated exon 51 skipping as represented by RT-PCR. (A) Primary healthy skeletal muscle cells treated with Ac0, Ac48, and analog morpholinos of eteplirsen (aEte) and drisapersen (aDri). (B) Immortalized DMD skeletal muscle cell line with the deletion of exons 48-50 (ID 6594). (C) Primary DMD skeletal muscle cells with exons 45-50 deletion (ID 4546).

Figure S4. In vivo test with mouse version (m) Ac0, Ac48, eteplirsen and drisapersen by the intramuscular injection (i.m.) at dose of 5 or 20 μg into tibialis anterior muscles of mdx52 mice. (A) Differences of mouse antisense sequences from human Ac0, Ac48, eteplirsen and drisapersen. (B) Exon skipping efficiency by RT-PCR. (C) Quantification of rescued dystrophin protein by Western blotting. Data represent mean ± SD from 3-4 mice in each group. NS, no significant difference. (D) Dystrophin-positive myofibers as detected by immunohistochemistry. Relative intensities in wild-type (WT) mouse images were generated with neutral density filters of the fluorescence microscope. The 100% fluorescence power used in WT mice was exposed to mdx52 mouse sections. Scale bar, 250 μm. Representative images are shown.

Table S1. Predicted skipping efficiency of 30-mer and 25-mer AOs for exon 51 skipping by the AO predictive algorithm (See the separate excel file).

Table S2. Primers used in RT-PCR.
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